Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nivolumab with paclitaxel/carboplatin in early-stage triple negative breast cancer
2024-512625-86-00Phase 2Completed
- Sponsor
- Breast Cancer Trials
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised trial of nivolumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Breast Cancer Trials. Primary endpoint: Pathological complete response (pCR) breast and nodes. Started Jan 2022; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-512625-86-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512625-86-00.